Gold prices steady ahead of Fed decision, Trump’s tariff deadline
LONDON - Alliance Pharma (LON:ALAPH) plc and Aegros Bidco Limited, a company backed by DBAY Affiliates and the ERES IV Fund, have announced the adjournment of the critical Court Meeting and General Meeting initially scheduled for today. These meetings are central to the proposed acquisition of Alliance Pharma by Aegros Bidco Limited, which was first publicized on January 10, 2025.
The acquisition, which aims to transfer all issued and to be issued ordinary share capital of Alliance Pharma to Bidco, is to be carried out via a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act. Details of the arrangement were outlined in a Scheme Document released by Alliance Pharma on January 31, 2025.
The decision to postpone the meetings was revealed on February 26, 2025, when the Alliance Directors expressed their intention to provide shareholders with additional time to consider the acquisition and to continue discussions. The adjourned meetings are now rescheduled for March 13, 2025, at 10:00 a.m. and 10:15 a.m., respectively, and will be held at Buchanan’s offices in London.
Shareholders of Alliance Pharma were initially notified of the meetings through notices contained in the Scheme Document, which detailed the terms and conditions of the proposed acquisition. The adjournment aims to ensure that shareholders have ample opportunity to evaluate the terms of the acquisition thoroughly.
The information regarding the adjournment of these meetings is based on a press release statement from Alliance Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.